Wissenschaftliche Arbeiten

Uzm. Dr. Burcu Gülbağcı

36 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)

    Cancers, 2026

    DOI 10.3390/cancers18030394 PMID 41681877 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  3. Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

    Cancers, 2026

    DOI 10.3390/cancers18142302 PMID 42512369 Frei zugänglicher VolltextQuelle: ORCID

  4. Short-Term Biceps Muscle Wasting Assessed by Serial Ultrasound as a Predictor of Survival Duration in Terminally Ill Cancer Patients: A Retrospective Cohort Study

    Medicina, 2026

    DOI 10.3390/medicina62020292 PMID 41752691 Frei zugänglicher VolltextQuelle: ORCID

  5. AGGF-1 Expression as a Predictive Biomarker for Anti-VEGF Therapy in Metastatic Colorectal Cancer

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.263054 Quelle: OpenAlex

  6. Beyond tumor burden: PET/CT-derived psoas muscle quality and survival outcomes in metastatic NSCLC patients treated with nivolumab.

    BMC cancer, 2026

    DOI 10.1186/s12885-026-16210-z PMID 42192342 Frei zugänglicher VolltextQuelle: ORCID

  7. Relationship Between Netrin-1 Staining and Neoadjuvant Treatment Response in HER2-Positive Locally Advanced Breast Cancer

    Cancer management and research, 2026

    DOI 10.2147/cmar.s551516 PMID 41710041 Frei zugänglicher VolltextQuelle: Europe PMC

  8. Investigating the FIB-4 index and PET/CT metabolic parameters for the differentiation status of hepatocellular carcinoma

    The Annals of Clinical and Analytical Medicine, 2026

    DOI 10.4328/acam.50067 Frei zugänglicher VolltextQuelle: OpenAlex

  9. Global research trends and intellectual structure of immune checkpoint inhibitor–associated pneumonitis: a bibliometric analysis (2000–2025

    Journal of Medicine and Palliative Care, 2026

    DOI 10.47582/jompac.1900478 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Association between serum preptin levels and bone metastasis in newly diagnosed prostate cancer: a prospective exploratory study

    Journal of bone oncology, 2026

    DOI 10.1016/j.jbo.2026.100794 PMID 42656999 Frei zugänglicher VolltextQuelle: OpenAlex

  11. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2570637 PMID 41103123 Frei zugänglicher VolltextQuelle: OpenAlex

  12. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  13. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  14. Real-world treatment patterns and prognostic indicators in upper tract urothelial carcinoma: A Turkish Oncology Group (TOG) study

    European Urology Open Science, 2025

    DOI 10.1016/s2666-1683(25)01751-3 Frei zugänglicher VolltextQuelle: OpenAlex

  15. Does toxicity of cyclin-dependent kinase 4/6 inhibitor predict treatment response in metastatic hormone-positive breast cancer patients?

    Oncology in Clinical Practice, 2025

    DOI 10.5603/ocp.101970 Frei zugänglicher VolltextQuelle: OpenAlex

  16. Prognostic Significance of HALP Score in Second-Line Nivolumab Treatment of Advanced Non-Small Cell Lung Cancer

    Namık Kemal Tıp Dergisi, 2025

    DOI 10.4274/nkmj.galenos.2024.76093 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  17. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

    BMC Cancer, 2024

    DOI 10.1186/s12885-024-13357-5 PMID 39736618 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  18. 223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.103245 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  19. Can Serum Albumin Level At Diagnosis Be A Guide for Clinical Features, Time to Treatment, and Response in Patients with Follicular Lymphoma?

    Namık Kemal Tıp Dergisi, 2024

    DOI 10.4274/nkmj.galenos.2024.35002 Frei zugänglicher VolltextQuelle: OpenAlex

  20. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-75293-5 PMID 39384975 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  21. Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy

    Oncology in Clinical Practice, 2024

    DOI 10.5603/ocp.101103 Frei zugänglicher VolltextQuelle: OpenAlex

  22. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  23. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

    Future Oncology, 2023

    DOI 10.2217/fon-2022-1287 PMID 37133230 22 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  24. 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study

    ESMO Open, 2023

    DOI 10.1016/j.esmoop.2023.101440 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  25. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

    Medicine, 2023

    DOI 10.1097/md.0000000000035950 PMID 37960746 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  26. Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment.

    PubMed, 2023

    DOI 10.26355/eurrev_202305_32341 PMID 37203857 Quelle: OpenAlex

  27. Temel Onkoloji

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1765 Quelle: OpenAlex

  28. Paraneoplastik Sendromlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1826 Frei zugänglicher VolltextQuelle: ORCID

  29. The role of neutrophil albumin ratio in predicting the stage of non-small cell lung cancer.

    PubMed, 2022

    DOI 10.26355/eurrev_202204_28621 PMID 35503633 17 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  30. Jinekolojik Tümörler ve Paraneoplastik Sendromlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1826.c17413 Quelle: OpenAlex

  31. Onkolojik Aciller

    Akademisyen Kitabevi eBooks, 2021

    DOI 10.37609/akya.352 Quelle: ORCID

  32. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

    Scientific Reports, 2021

    DOI 10.1038/s41598-021-93659-x PMID 34239026 12 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  33. COVID-19 prevalence and oncologic outcomes of asymptomatic patients with active cancer who received chemotherapy

    Sakarya Üniversitesi Kurumsal Açık Akademik Arşivi, 2021

    DOI 10.19193/0393-6384_2021_1_103 3 Zitationen (OpenAlex) Quelle: OpenAlex

  34. Has the COVID-19 Pandemic Increased Mortality Among Patients with Cancer Receiving Systemic Anticancer Treatments?

    Journal of College of Physicians And Surgeons Pakistan, 2021

    DOI 10.29271/jcpsp.2021.01.s66 PMID 33650412 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  35. Evaluation of the relationship of disease activity with neutrophile to lymphocyte ratio and platelet to lymphocyte ratio in patients with peptic ulcer and gastritis

    International Journal of Research in Medical Sciences, 2020

    DOI 10.18203/2320-6012.ijrms20204869 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  36. Sakarya Üniversitesi Tıbbi Onkoloji Kliniği 2017-2018 Yılı Akciğer Kanseri İstatistikleri

    DergiPark (Istanbul University), 2020

    Frei zugänglicher VolltextQuelle: OpenAlex